Literature DB >> 11861773

Excitotoxicity: perspectives based on N-methyl-D-aspartate receptor subtypes.

David R Lynch1, Rodney P Guttmann.   

Abstract

Since excitotoxicity has been implicated in a variety of neuropathological conditions, understanding the pathways involved in this type of cell death is of critical importance to the future clinical treatment of many diseases. The N-methyl-D-aspartate (NMDA) receptor has become a primary focus of excitotoxic research because early studies demonstrated that antagonism of this receptor subtype was neuroprotective. However, initial pharmacological agents were not clinically useful due to the adverse effects of complete NMDA receptor blockade. Understanding the biochemical properties of the multitude of NMDA receptor subtypes offers the possibility of developing more effective and clinically useful drugs. With the discovery of the basis of heterogeneity of NMDA receptors through molecular biological approaches, many new potential therapeutic targets have been uncovered, and several model systems have been developed for the study of NMDA receptor-mediated cell death. This review discusses these models and the current understanding of the relationship between NMDA receptor subtypes and excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861773     DOI: 10.1124/jpet.300.3.717

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

Review 1.  AMPA receptor-mediated neurotoxicity: role of Ca2+ and desensitization.

Authors:  Aase Frandsen; Arne Schousboe
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

2.  Selective activation induced cleavage of the NR2B subunit by calpain.

Authors:  Kelly L Simpkins; Rodney P Guttmann; Yina Dong; Zhaoming Chen; Set Sokol; Robert W Neumar; David R Lynch
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

3.  N-methyl-D-aspartate receptor mechanosensitivity is governed by C terminus of NR2B subunit.

Authors:  Pallab Singh; Shachee Doshi; Jennifer M Spaethling; Adam J Hockenberry; Tapan P Patel; Donna M Geddes-Klein; David R Lynch; David F Meaney
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

Review 4.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

5.  NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus.

Authors:  Rana A Al-Hallaq; Thomas P Conrads; Timothy D Veenstra; Robert J Wenthold
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

Review 6.  Calpain and synaptic function.

Authors:  Hai-Yan Wu; David R Lynch
Journal:  Mol Neurobiol       Date:  2006-06       Impact factor: 5.590

7.  Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice.

Authors:  R W Gould; D Dencker; M Grannan; M Bubser; X Zhan; J Wess; Z Xiang; C Locuson; C W Lindsley; P J Conn; C K Jones
Journal:  ACS Chem Neurosci       Date:  2015-08-05       Impact factor: 4.418

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

10.  Ketamine-induced neuronal damage and altered N-methyl-D-aspartate receptor function in rat primary forebrain culture.

Authors:  Fang Liu; Tucker A Patterson; Natalya Sadovova; Xuan Zhang; Shuliang Liu; Xiaoju Zou; Joseph P Hanig; Merle G Paule; William Slikker; Cheng Wang
Journal:  Toxicol Sci       Date:  2012-10-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.